BIOLASE (NASDAQ:BIOL) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Tuesday. The firm set a “sell” rating on the medical technology company’s stock.

Several other brokerages also recently issued reports on BIOL. Ascendiant Capital Markets cut their price objective on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Benchmark reiterated a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a research report on Monday, August 12th. Finally, Maxim Group downgraded BIOLASE from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 24th.

BIOLASE Price Performance

BIOLASE stock opened at $0.05 on Tuesday. The company has a market capitalization of $1.74 million, a PE ratio of 0.00 and a beta of 0.66. BIOLASE has a one year low of $0.04 and a one year high of $2.26. The business has a 50 day simple moving average of $0.06 and a 200 day simple moving average of $0.12.

BIOLASE (NASDAQ:BIOL) last posted its earnings results on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. The company had revenue of $11.56 million for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 41.65%.

Institutional Investors Weigh In On BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC lifted its position in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the quarter. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is currently owned by hedge funds and other institutional investors.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.